At the negotiation site of the 2020 medical insurance catalog, what are the famous scenes of the so

On December 28, the press conference of the National Medical Insurance Catalogue was held as scheduled in Jiangsu Building. A total of 119 drugs were successfully negotiated, of which 96 were in the catalogue and 23 were outside the catalogue。At the scene of this negotiation, there were many famous bargaining scenes.

According to CCTV News, at the negotiation site of Kangai injection, a first-class cancer drug, a representative of a pharmaceutical company in Northeast China said "modestly" and bluntly said that "our companies in Northeast China are not very good at speaking". The negotiator smiled and said bluntly: "Don't reduce the price like squeezing toothpaste, it's not easy to negotiate!"

This sentence has also become a golden sentence at the negotiation site, and in the end, the representative of the pharmaceutical company knocked on the calculator to calculate, and then typed ** to ask for instructions, and finally agreed. At the negotiation site of the joint targeted tumor drug for melanoma, there are also frequent golden sentences. Something like "7 and 4 are really bad together, it's really unlucky for patients" and "Can't you drop another dollar?"

In the end, this drug was sold at a price of 739.

In addition, at the negotiation site, there was a representative of a pharmaceutical company with "08" every time, and the negotiator said, "You just want to ask for an auspicious number". Hehe, I think this representative is quite interesting, sometimes people are a little superstitious about something just to be auspicious. Our negotiators will often generate a reserve price through a large number of scientific calculations in the early stage, and then through the negotiation rules, let the pharmaceutical companies make the greatest concession space and strive for the greatest benefits for the insured.

This negotiation has successively staged "soul bargaining", and it is also the continuous deepening of the reform of China's medical security system, and the establishment of some new mechanisms. Netizens also praised this. There are comments that "the Northeast irons are upright", and there are also particularly warm comments that "every dollar that is talked about warms the hearts of all patients."", some netizens said that if the Medical Insurance Bureau asked Li Jiaqi to negotiate, what would be the scene.

I have to say that these famous bargaining scenes really make people want to laugh and move. Thank you so much!

At the negotiation site of the 2020 medical insurance catalog, the famous scene of "soul" is very exciting, and experts said that bargaining is like squeezing toothpaste, which can squeeze a little is a little, for example, the soul version of the bargaining is not only wonderful with a difference of 4 cents, but also such a scene: after the representative of the pharmaceutical company, the negotiator replied, "Can't you reduce another dollar?" "10 yuan and 5 points can be removed", "7 and 4 are really not good together".

There are also "10 yuan and 5 points can be removed", "9 yuan, 9 corners and 9 points are very good", the routine of negotiators trying to reduce the price has also aroused praise from netizens that "the picture causes comfort".

The first famous scene is the price reduction, and the negotiator said that the price reduction should not be like squeezing toothpaste. The second famous scene is the number of **, in order to draw an auspicious number, the final mantissa is eight.

The most impressive famous scene is the negotiation between the person in charge and the medical representative, who has been bargaining for "a penny", reflecting the perspective of the people in handling things.

There were two scenes that impressed me the most in this medical insurance negotiation.

1.The representative of a pharmaceutical company has a mantissa 08 in each round, in order to make an auspicious and a few more profits, but because of this auspicious number, he was successfully cut by the negotiators by 217 yuan.

2.As soon as a representative of a pharmaceutical company in the Northeast opened his mouth, the Northeast people would not bargain, so in the end, they were successfully bargained and cut the **.

In 2023, the two major rules for the negotiation of dissolution and merger of medical insurance are the "Rules for Negotiating Drug Renewals" and the "Rules for Non-exclusive Drug Bidding".

1. Rules for Negotiating Drug Renewal

Rules for negotiating drug renewals" proposed that negotiated drugs that have reached 8 years should be included in the regular catalogue management; For drugs that have been negotiated for less than 8 years, if the price reduction is triggered by the renewal of the contract or the addition of new indications in a simplified manner for the varieties that have reached or exceeded the continuous agreement period of 4 years, the price reduction will be halved.

According to the National Health Insurance Administration, the above rules are based on international experience, that is, it takes about 8 to 10 years for a drug to reach its peak from marketing to sales. Thanks to the promotion of the dynamic adjustment mechanism, the process in the Chinese market has accelerated. The above adjustments are conducive to stabilizing corporate expectations, reducing the pressure of price reduction in the later stage, and reducing the possibility of failure to renew.

2. Rules for Non-Exclusive Drug Bidding

In accordance with the Bidding Rules, the medical insurance party organizes the calculation experts to calculate according to the procedure, and proposes the willingness to pay for the medical insurance as the entry threshold for the generic drug.

As long as there is one enterprise participating and not higher than the willingness to pay for medical insurance, the generic drug will be included in the medical insurance category B catalog, otherwise the generic drug will not be included. The enterprise** shall not be higher than the provincial minimum bid price valid within 2 years before the declaration deadline and the market retail ** submitted at the time of declaration**.

Changes in Medicare in 2023:

1. If the employer and the insured personnel participate in the employee medical insurance for the first time, and the arrears have not been paid or the arrears have been paid for more than 3 months, they will enjoy the basic medical insurance treatment after 3 months from the month of payment; If the arrears are less than 3 months (inclusive) and have been paid, they will enjoy the basic medical insurance treatment from the next day of payment.

The new regulations for annual medical insurance reimbursement are as follows: unified medical insurance reimbursement ratio. After the implementation of the new regulations, the reimbursement ratio of medical insurance will be uniformly adjusted to 80%, and the items covered mainly include hospitalization expenses, outpatient expenses, drug expenses, etc. Increase hospitalization reimbursement items.

3. New regulations on employee medical insurance: if the insurance is suspended for 3 months, it will be regarded as surrender, and if the medical insurance is suspended for more than 3 months, it will be deemed to be automatically surrendered. If the cumulative number of years of retirement contribution is insufficient, you can make up the payment.

The above content refers to: Encyclopedia - Negotiate Drug Renewal Rules.

The above content refers to: Encyclopedia - Non-exclusive Drug Bidding Rules.

The reporter of "Economic Information Daily" learned that the 2022 medical insurance drug list access negotiations will be officially in early December. At that time, a number of innovative drugs and large varieties of drugs will be included in the medical insurance catalog, and the coverage of medical insurance will be further expanded. Remegen's vedicitumab for injection, Akeso's bispecific antibody drug cadonilimab, and WuXi Ju Norreita autoleucel injection, which is currently purchased at a price of 1.29 million yuan, will also start the journey of medical insurance negotiations, and it is worth paying attention to whether it can enter the medical insurance.

Liu Guoen, director of the China Health Economics Research Center of Peking University, said that drug value evaluation is a scientific concept to determine the average value of drugs "based on value".

Since 2018, the negotiation of access to the National Medical Insurance Drug List has been carried out for four consecutive years, and a total of 250 innovative and life-saving drugs have been added to the list through negotiations, with an average decrease of more than 50%. In 2021, a total of 100 million people will be reimbursed for 221 negotiated drugs during the agreement period, reducing the burden on patients by 100 million yuan.

It is reported that in 2022, 344 of the 490 declared drugs in the national talks passed the preliminary review. Among them, there are 199 drugs not included in the catalogue, including 144 exclusive varieties of Western medicines and 14 exclusive varieties of Chinese patent medicines. From the perspective of drug category adjustment, the adjustment of the medical insurance catalogue adheres to the bottom-line principle of "ensuring the basics".

Liu Guoen pointed out that taking 2021 as an example, the 74 new drugs cover 18 types of tumor drugs, 20 kinds of drugs for chronic diseases such as hypertension and diabetes, 15 kinds of anti-infective drugs such as hepatitis C and AIDS, and 7 drugs for rare diseases, which means that the protection for different groups of people is deepening. He said that the negotiation of the medical insurance catalogue is a good way to break people's inherent concept of "innovative drugs = sky-high drugs". In 2021, 67 of the 85 drugs involved in the negotiation outside the catalogue were successfully negotiated, with a success rate and a high price reduction, both higher than in 2019 and 2020.

Taking anti-tumor drugs as an example, from 2018 to 2021, the number of anti-tumor drugs has been maintained at 20% or more, and the average decline rate has remained at 44% or more. In 2018, the success rate of special negotiations on anti-cancer drugs was as high, with an average reduction rate, which alleviated the drug problem of cancer patients.

December 31, 2022.

The notice clarifies that the 2022 annual resident medical insurance centralized insurance payment period is in principle from September 1 to December 31, 2021. For co-ordinated areas that fail to reach the prescribed participation rate as scheduled, the centralized insurance payment period can be appropriately extended to February 28, 2022. After the newborn is registered and paid within 90 days after birth, the eligible medical expenses incurred since the date of birth can be included in the medical insurance reimbursement;

Medical insurance for 2022 will end on December 31, 2021 at the latest. In 2022, the payment of medical insurance has begun in many areas, and some areas may start in October, and this year's unified payment standard is 320 yuan, and the payment date is until the end of December. There are a variety of channels to pay the fee, you can pay the fee on the mobile phone WeChat applet, you can also go to the bank agency, or you can go to the village agency to pay the fee.

Medical insurance for 2022 is no later than December 31, 2021. In 2022, the payment of medical insurance for urban and rural residents, now some areas have begun, and some areas may open in October and return to the beginning of the payment, this year the unified national standard is 320 yuan, and a variety of payment methods have also been opened, which can be paid on the mobile phone, bank payment or payment at the agency point.